Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1 clinical trials · Condition
◉ Watch Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT02780830) | AstraZeneca | 2016-06-01 |
Track Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.